Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

被引:0
作者
T. H. Han
R. Chen
R. Advani
R. B. Berryman
S. E. Smith
A. Forero-Torres
J. D. Rosenblatt
M. R. Smith
J. Zain
N. N. Hunder
A. Engert
机构
[1] Seattle Genetics,
[2] Inc.,undefined
[3] City of Hope National Medical Center,undefined
[4] Stanford University Medical Center,undefined
[5] Baylor University Medical Center,undefined
[6] Loyola University Medical Center,undefined
[7] University of Alabama at Birmingham,undefined
[8] University of Miami Miller School of Medicine,undefined
[9] Cleveland Clinic,undefined
[10] Fox Chase Cancer Center,undefined
[11] Columbia University Medical Center,undefined
[12] New York University Cancer Institute,undefined
[13] University Hospital of Cologne,undefined
来源
Cancer Chemotherapy and Pharmacology | 2013年 / 72卷
关键词
Brentuximab vedotin; Antibody–drug conjugate; QT interval; CD30-positive hematologic malignancies;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:241 / 249
页数:8
相关论文
共 29 条
  • [1] Wu AM(2005)Arming antibodies: prospects and challenges for immunoconjugates Nat Biotechnol 23 1137-1146
  • [2] Senter PD(2008)Antibody-drug conjugates for cancer therapy Cancer J 14 154-169
  • [3] Carter PJ(2006)Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J Biol Chem 281 10540-10547
  • [4] Senter PD(2003)cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102 1458-1465
  • [5] Sutherland MS(2005)International conference on harmonization; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability Notice Fed Regist 70 61134-61135
  • [6] Sanderson RJ(2007)Revised response criteria for malignant lymphoma J Clin Oncol 25 579-586
  • [7] Gordon KA(2008)Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review J Clin Pharmacol 48 13-18
  • [8] Francisco JA(2001)Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling Drug Saf 24 323-351
  • [9] Cerveny CG(2010)Interval shortening: potential harbinger of proarrhythmia and regulatory perspectives Br J Pharmacol 159 58-69
  • [10] Meyer DL(2012)Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase 2 study J Clin Oncol 30 2190-2196